Provided by Tiger Trade Technology Pte. Ltd.

T. Rowe Price Health Care ETF

33.81
+0.70602.13%
Post-market: 33.810.00000.00%16:00 EDT
Volume:4K
Turnover:120.40K
Market Cap:32.96M
PE:- -
High:33.88
Open:33.80
Low:33.74
Close:33.10
52wk High:36.72
52wk Low:27.57
Shares:975.00K
Float Shares:975.00K
Volume Ratio:0.80
T/O Rate:0.37%
Dividend:0.16
Dividend Rate:0.48%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug

TIPRANKS
·
Oct 06

Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement

TradingKey
·
Oct 06

Sector Update: Healthcare Stocks Rise Monday Afternoon

MT Newswires Live
·
Oct 06

Lilly Expands Oncology Footprint with FDA Win for Pancreatic Cancer Drug

Dow Jones
·
Oct 05

UnitedHealth Group Faces Texas AG Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05

Eli Lilly treatment of pancreatic cancer granted orphan designation

TIPRANKS
·
Oct 05

UnitedHealth Group Faces AG Paxton Investigation Over Coverage Practices

MT Newswires Live
·
Oct 05

UnitedHealth under investigation by Texas AG amid alleged unlawful practices

TIPRANKS
·
Oct 05

TRex Bio Files for Nasdaq IPO

MT Newswires Live
·
Oct 05

Abbott Laboratories Receives FDA Approval to Include Interactive Features in CardioMEMS Heart Monitor

MT Newswires Live
·
Oct 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Oct 05

Abbott Receives FDA Approval for New Cardiomems HF System Capabilities That Help Patients Engage in the Care of Their Heart Condition

THOMSON REUTERS
·
Oct 05

Abbott - Cardioguide HF App and Dynamic Treatment Plan to be Available Later This Year

THOMSON REUTERS
·
Oct 05

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins

THOMSON REUTERS
·
Oct 05

Eli Lilly Presents New Ebglyss Data from Phase 3 ADorable-1 Pediatric Atopic Dermatitis Study at Fall Clinical 2026

Reuters
·
Oct 05

Nurix, Gilead Extend Research Term for Oncology Program by Two Years for $10 Million Fee

Reuters
·
Oct 05

Nurix Extends Gilead Collaboration for Oncology Program

Reuters
·
Oct 05

Nurix - Eligible for up to $1.30 Bln in Total Payments as of May 31, 2026

THOMSON REUTERS
·
Oct 05

Nurix - Eligible for Mid-Single-Digit to Low-Teens Percentage Tiered Royalties

THOMSON REUTERS
·
Oct 05

Nurix - to Receive $10 Mln Research Term Extension Fee

THOMSON REUTERS
·
Oct 05